# Phase 1/2 Uterine Cervical cancer trials: 36 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials in phase 1/2 for Uterine Cervical cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Uterine Cervical cancer trials: 36 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/uterine-cervical-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 36
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| June 25, 2026 | NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | University of Nebraska | Phase 1/2 | Not yet recruiting | Prostate Cancer, Uterine Cancer, Cervical Cancer, Anal Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668284) |
| April 21, 2026 | NCT07542717 | ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1/2 | Not yet recruiting | Recurrent or Metastatic Cervical Cancer | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07542717) |
| February 25, 2026 | NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | Sichuan Enray Pharmaceutical Sciences Company | Phase 1/2 | Recruiting | Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer, Colorectal Cancer, Cervical Cancer, Vulva Cancer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07433283) |
| November 24, 2025 | NCT07245381 | Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Cervix Cancer | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07245381) |
| September 24, 2025 | NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Radiopharm Theranostics, Ltd | Phase 1/2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer... | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189871) |
| August 7, 2025 | NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Terremoto Biosciences Inc. | Phase 1/2 | Recruiting | Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma... | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07109726) |
| July 23, 2025 | NCT07080216 | Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Recruiting | Cervical Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07080216) |
| July 14, 2025 | NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | University of California, Irvine | Phase 1/2 | Recruiting | Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07064018) |
| May 29, 2025 | NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Advanced Solid Tumors, Advanced Breast Cancer | 233 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06993844) |
| May 16, 2025 | NCT06975410 | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | Yuhan Corporation | Phase 1/2 | Recruiting | EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975410) |
| April 24, 2025 | NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Tanabe Pharma America, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943521) |
| March 5, 2025 | NCT06859775 | SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | Recurrent or Metastatic Cervical Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859775) |
| February 7, 2025 | NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors | University of Arizona | Phase 1/2 | Recruiting | Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06814496) |
| January 29, 2025 | NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | Evopoint Biosciences Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06799637) |
| November 4, 2024 | NCT06672653 | Tolerance and Effectiveness of C14 on HPV Infection | MGB Pharma | Phase 1/2 | Not yet recruiting | HPV-induced Cancers, HPV Infections, HIV, Cervical Cancers, Trial, C14, Monoterpenoid Zinc Tetra-ascorbo-camphorate | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06672653) |
| July 31, 2024 | NCT06529809 | Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer | Washington University School of Medicine | Phase 1/2 | Recruiting | Locally Advanced Cervical Carcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06529809) |
| July 17, 2024 | NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | SCG Cell Therapy Pte. Ltd. | Phase 1/2 | Not yet recruiting | HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06505551) |
| April 24, 2024 | NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Cancer Research UK | Phase 1/2 | Recruiting | Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms... | 167 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06380816) |
| March 26, 2024 | NCT06330064 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors... | Daiichi Sankyo | Phase 1/2 | Recruiting | Recurrent or Metastatic Solid Tumors | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06330064) |
| March 20, 2024 | NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | Theravectys S.A. | Phase 1/2 | Recruiting | HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06319963) |
| February 20, 2024 | NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | GeneMedicine Co., Ltd. | Phase 1/2 | Recruiting | Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Cervical Cancer, Breast Cancer | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06265025) |
| February 2, 2024 | NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | ModeX Therapeutics, An OPKO Health Company | Phase 1/2 | Recruiting | Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric... | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06239194) |
| September 21, 2023 | NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Neonc Technologies, Inc. | Phase 1/2 | Recruiting | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal... | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06047379) |
| July 13, 2023 | NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | Cancer Research UK | Phase 1/2 | Recruiting | Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05944237) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Cancer Research UK | 2 |
| Arvinas Inc. | 1 |
| University of Nebraska | 1 |
| Neonc Technologies, Inc. | 1 |
| GI Innovation, Inc. | 1 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 1 |
| [Evopoint Biosciences Inc.](https://specstream.ai/data/clinical-trials/company/evopoint-biosciences-inc) | 1 |
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| ModeX Therapeutics, An OPKO Health Company | 1 |
| University of Arizona | 1 |
| GeneMedicine Co., Ltd. | 1 |
| [Yuhan Corporation](https://specstream.ai/data/clinical-trials/company/yuhan-corporation) | 1 |
| LigaChem Biosciences, Inc. | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| Marengo Therapeutics, Inc. | 1 |
| Sichuan Enray Pharmaceutical Sciences Company | 1 |
| MGB Pharma | 1 |
| [Tanabe Pharma America, Inc.](https://specstream.ai/data/clinical-trials/company/tanabe-pharma-america-inc) | 1 |
| Terremoto Biosciences Inc. | 1 |
| SCG Cell Therapy Pte. Ltd. | 1 |
| DualityBio Inc. | 1 |
| University of California, Irvine | 1 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 22 |
| China | 9 |
| Spain | 5 |
| Japan | 5 |
| South Korea | 4 |
| Canada | 3 |
| France | 3 |
| Ireland | 3 |
| Australia | 3 |
| Germany | 3 |
| Italy | 3 |
| United Kingdom | 2 |
| Portugal | 2 |
| Taiwan | 2 |
| Belgium | 2 |
| Netherlands | 2 |
| Democratic Republic of the Congo | 1 |
| Puerto Rico | 1 |
| Israel | 1 |
| Argentina | 1 |
| Brazil | 1 |
| Chile | 1 |
| Mexico | 1 |
| Poland | 1 |
| Turkey (Türkiye) | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Lebanese restaurants in the United States](https://specstream.ai/data/businesses/lebanese-restaurants/united-states)
- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [Sleep medicine clinics in the United States](https://specstream.ai/data/businesses/sleep-medicine-clinics/united-states)
- [Truck rental companies in the United States](https://specstream.ai/data/businesses/truck-rental-companies/united-states)
- [Allergy and immunology practices in the United States](https://specstream.ai/data/businesses/allergy-and-immunology-practices/united-states)
